This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/pubchem-substance/
n6http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/iuphar/
n17http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/guide-to-pharmacology/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB03107/identifier/chebi/

Statements

Subject Item
n2:DB03107
rdf:type
n3:Drug
n3:description
An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported. [PubChem]
n3:group
experimental
owl:sameAs
n6:DB03107 n7:DB03107
dcterms:title
Beta-Alanine
adms:identifier
n10:239 n11:46507739 n12:C00099 n13:BAL n14:2365 n15:2365 n16:16958 n17:DB03107
n3:synthesisReference
Erwin Grill, Ernst-Ludwig Winnacker, Meinhart H. Zenk, "Cysteine-rich peptides having gamma-glutamic acid and beta-alanine units, a process for their preparation and their use." U.S. Patent US4883861, issued March, 1978.
n3:IUPAC-Name
n4:271B4FCE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4FD4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4FD3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4FD0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4FD1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4FD2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4FE4-363D-11E5-9242-09173F13E4C5 n4:271B4FCC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4FCA-363D-11E5-9242-09173F13E4C5 n4:271B4FE6-363D-11E5-9242-09173F13E4C5 n4:271B4FCD-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4FCB-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4FE7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4FDA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4FDB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4FD5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4FD6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4FD8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4FD7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4FD9-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
107-95-9
n3:Bioavailability
n4:271B4FE0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4FE2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4FE3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4FE5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4FDF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4FDE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4FE1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4FCF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4FDC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4FDD-363D-11E5-9242-09173F13E4C5